FUKUSHIMA JOURNAL OF MEDICAL SCIENCE
Online ISSN : 2185-4610
Print ISSN : 0016-2590
ISSN-L : 0016-2590
Real-world characteristics of endovascular treatment for middle cerebral artery M2 segment occlusion in Fukushima Prefecture: a prospective multicenter registry study
Takuya Maeda, Takao Kojima, Mudathir Bakhit, Haruhiko Kikuta, Yuhei Ito, Kiyoshi Saito, Masazumi Fujii
Author information
JOURNAL OPEN ACCESS FULL-TEXT HTML Advance online publication

Article ID: 26-00026

Details
Abstract

Background : The role of endovascular treatment (EVT) in middle cerebral artery M2 segment occlusion remains inconclusive, particularly in rural areas with aging populations. We characterized EVT and medical management (MM) for M2 occlusion in Fukushima Prefecture, Japan, and explored clinical factors associated with outcomes.

Methods : We analyzed a prospective multicenter acute ischemic stroke registry (July 2020-June 2022; 11 stroke centers). Patients with M2 occlusion were classified into EVT or MM groups; characteristics, workflow metrics, and outcomes were described and referenced against previously reported series.

Results : Among 210 patients, 34 had M2 occlusion (EVT, n=10; MM, n=24). At 90 days, functional independence (modified Rankin Scale [mRS] 0-2) was 40.0% (EVT) and 45.8% (MM); symptomatic intracerebral hemorrhage, 0% and 4.2%; mortality, 20.0% and 12.5%; successful reperfusion, 70.0% (EVT). Both groups were older than in previous reports (median 81 years). The EVT group also received rt-PA less often (30.0%) and had longer puncture-to-reperfusion times (81 minutes), whereas the MM group had lower pre-stroke independence (67%) and higher mortality, despite lower severity.

Conclusion : Advanced age, delayed reperfusion, and greater pre-stroke dependency distinguished this rural cohort from previous reports and likely account for its outcomes, underscoring the need for locally tailored patient selection for EVT in M2 occlusion.

Content from these authors
© 2026 The Fukushima Society of Medical Science

This article is licensed under a Creative Commons [Attribution-NonCommercial-ShareAlike 4.0 International] license.
https://creativecommons.org/licenses/by-nc-sa/4.0/
Next article
feedback
Top